Evaluation of dosing strategy for pembrolizumab for oncology indications

Journal for Immunotherapy of Cancer
T FreshwaterJ A Stone

Abstract

Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies; however, following availability of PK data, the need for weight-based dosing for pembrolizumab was reassessed. A previously established population PK (popPK) model as well as exposure-response results from patients with advanced melanoma or non-small cell lung cancer (NSCLC) were used to evaluate the potential application of a fixed dosing regimen with the aim of maintaining pembrolizumab exposures within the range demonstrated to provide near maximal efficacy and acceptable safety. Individual PK exposures for the selected fixed dosing regimen from recently completed trials with head and neck cancer, NSCLC, microsatellite instability high (MSI-H) in colorectal cancer (CRC) and urothelial cancer were used to confirm acceptability. To determine whether fixed dosing would maintain exposures within the range of clinical experience, the individual AUC distributions with fixed dosing were compared with the range of exposures from the pembrolizumab doses that were evaluated in early studies (2 mg/kg Q3W, 10 m...Continue Reading

References

Jul 22, 2009·Journal of Clinical Pharmacology·Diane D WangKourosh Parivar
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Sep 8, 2010·Clinical Pharmacokinetics·Nathanael L Dirks, Bernd Meibohm
Jan 6, 2011·British Journal of Clinical Pharmacology·Stephen B DuffullHelen R Winter
Jan 15, 2011·Journal of Clinical Pharmacology·Shuzhong ZhangDiane D Wang
Jan 20, 2012·Clinical Pharmacokinetics·Shuang BaiMark J Dresser
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Jan 23, 2016·Expert Opinion on Biological Therapy·Sung Hee LimMyung-Ju Ahn
Apr 20, 2016·JAMA : the Journal of the American Medical Association·Antoni RibasCaroline Robert
Apr 28, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ChatterjeeØ Fløtten
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M ChowTanguy Y Seiwert
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 30, 2016·CPT: Pharmacometrics & Systems Pharmacology·M S ChatterjeeD P de Alwis

❮ Previous
Next ❯

Citations

Sep 19, 2017·Journal of Clinical Pharmacology·Jennifer ShengManish Gupta
Dec 9, 2017·Future Oncology·Kevin T LundgrenJoaquim Bellmunt
Jun 27, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Ochoa de OlzaE Garralda
Aug 29, 2018·Immunotherapy·Emily Feld, Tara C Mitchell
Sep 15, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G V LongX Zhao
Feb 2, 2019·Clinical Pharmacology in Drug Development·Ken Ogasawara, G Caleb Alexander
Mar 1, 2019·Clinical Pharmacokinetics·Maddalena CentanniJ G Coen van Hasselt
May 23, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M de Miguel, E Calvo
Jul 19, 2019·Expert Opinion on Biological Therapy·Won Jin Ho, Ranee Mehra
Jul 20, 2019·Expert Opinion on Biological Therapy·Grégoire MarretChristophe Le Tourneau
Apr 9, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Daniel G CoitAnita M Engh
Nov 5, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aurelien MarabelleLuis A Diaz
Sep 26, 2019·Clinical Pharmacology and Therapeutics·Ana M NovakovicAkash Khandelwal
Dec 28, 2019·Cancers·Sarah L PicardoAaron R Hansen
Jul 30, 2017·The Oncologist·Jeroen J M A HendrikxJos H Beijnen
Feb 23, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstPaul Baas
Jan 20, 2020·Clinical Pharmacology and Therapeutics·Yulia VugmeysterAkash Khandelwal
Mar 7, 2020·Journal of Clinical Apheresis·Philipp GaucklerAndreas Kronbichler
Oct 28, 2019·Clinical Pharmacokinetics·Belén P SolansIñaki F Trocóniz
Apr 24, 2020·British Journal of Clinical Pharmacology·Yara AbdouMarc S Ernstoff
May 20, 2020·British Journal of Clinical Pharmacology·Cody J PeerMark J Ratain
May 13, 2020·British Journal of Clinical Pharmacology·Geoffrey Alan WatsonAnna Spreafico
Apr 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Justine ClarenneFlorian Slimano
Dec 30, 2017·Expert Review of Anticancer Therapy·Nora SundahlPiet Ost
Sep 3, 2020·International Journal of Cancer. Journal International Du Cancer·Elizabeth DudnikUNKNOWN Israel Lung Cancer Group
May 10, 2020·British Journal of Clinical Pharmacology·Vishal NavaniAndre Van Der Westhuizen
Jun 17, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Ashley JangAlison Pow
Aug 20, 2017·Current Hematologic Malignancy Reports·Lorenzo Falchi
Mar 15, 2019·Clinical Pharmacokinetics·Hannah Yejin KimAlan V Boddy
Apr 7, 2018·Therapeutic Advances in Hematology·Polina Shindiapina, Lapo Alinari
Jul 7, 2019·Advances in Therapy·Justin J WilkinsAkash Khandelwal

❮ Previous
Next ❯

Software Mentioned

PopPK
SigmaPlot
R

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.